Physician and patient preferences for oral anticoagulation therapy decision-making in atrial fibrillation: Results from a national best-worst scaling survey in Turkey (PREF-AF)

Basit Öğe Kaydı
dc.contributor.authorKılıçkesmez, Kadriye
dc.contributor.authorAras, Dursun
dc.contributor.authorDeğertekin, Muzaffer
dc.contributor.authorÖzer, Nagihan
dc.contributor.authorHacıbedel, B.
dc.contributor.authorHelvacıoğlu, K.
dc.contributor.authorKoç, U.
dc.contributor.authorÖlmez, A.
dc.contributor.authorErgene, Oktay
dc.date.accessioned2023-03-17T05:56:09Z
dc.date.available2023-03-17T05:56:09Z
dc.date.issued2022
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Kardiyoloji Ana Bilim Dalı
dc.description.abstractObjectives Cost-utility modeling informs reimbursement decisions and is based on the premise that health outcome improvements can be expressed as disease-independent utility scores. Previous cost-utility analyses of anti-calcitonin gene-related peptide therapies expressed the utility gain as a function of monthly migraine days (MMDs). Exploring the presence of an additional treatment effect on utility after controlling for MMDs can be insightful. This post hoc analysis of the DELIVER clinical trial (NCT04418765) for the preventive treatment of migraine aims to communicate the impact of eptinezumab on health utility scores. Methods Utility scores were estimated using data from study visits at which the Migraine-Specific Quality of Life Questionnaire (MSQ) was completed. MSQ scores were then mapped to EQ-5D-3L using previously published algorithms. A linear mixed model evaluating the effect of eptinezumab compared to placebo using change from baseline at week 12 and 24, adjusted for MMDs, was generated, and a fixed intercept for each study arm was used to estimate if eptinezumab effected points compared to placebo beyond MMD reduction.
dc.identifier.citationKılıçkesmez, K., Aras, D., Değertekin, M., Özer, N., Hacıbedel, B., Helvacıoğlu, K. ... Ergene, O. (2022). Physician and patient preferences for oral anticoagulation therapy decision-making in atrial fibrillation: Results from a national best-worst scaling survey in Turkey (PREF-AF). Value in Health içinde (S436-S436. ss.).
dc.identifier.endpageS436
dc.identifier.issn1098-3015
dc.identifier.issn1524-4733
dc.identifier.issue12
dc.identifier.startpageS436
dc.identifier.urihttps://hdl.handle.net/20.500.12511/10627
dc.identifier.volume25
dc.identifier.wos000897594903216en_US
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.institutionauthorAras, Dursun
dc.language.isoen
dc.publisherElsevier Science Inc.
dc.relation.ispartofValue in Healthen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/embargoedAccess
dc.subjectPREF-AF
dc.subjectDecision-Making in Atrial Fibrillation
dc.subjectOral Anticoagulation Therapy
dc.subjectPatient Preferences
dc.titlePhysician and patient preferences for oral anticoagulation therapy decision-making in atrial fibrillation: Results from a national best-worst scaling survey in Turkey (PREF-AF)
dc.typeConference Object

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
Dursun-Aras-2022.pdf
Boyut:
391.01 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Bildiri Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu